跳至主導覽 跳至搜尋 跳過主要內容

Revisiting COX-2 inhibitors for Alzheimer's disease as multitargeted ligands: Development of 4-hydrazono-pyrazolidinediones with tuned COX selectivity profile and improved cellular potency

  • Reham Waheed
  • , Zeinab Mostafa
  • , Michael Emad
  • , Sarah S. Darwish
  • , Rosa Purgatorio
  • , Daniela Valeria Miniero
  • , Annalisa De Palma
  • , Tzu Peng Cheng
  • , Ting Yu Wang
  • , Yu Cheng Chen
  • , Ahmed M. El Kerdawy
  • , Moustafa Gabr
  • , Marco Catto
  • , Ashraf H. Abadi
  • , Tsong Long Hwang*
  • , Mohammad Abdel-Halim*
  • *此作品的通信作者
  • German University in Cairo
  • University of Hertfordshire Hosted by Global Academic Foundation
  • University of Bari
  • 'Giuseppe Degennaro' LUM University
  • Chang Gung University
  • Kaohsiung Medical University
  • Chang Gung University of Science and Technology
  • University of Lincoln
  • Cairo University
  • Cornell University

研究成果: 期刊稿件 › 文章 › 同儕審查

1 引文 斯高帕斯(Scopus)

摘要

Herein, we expand on our previously synthesized 4-hydrazono-pyrazolidinedione COX-2 inhibitors as multitargeted agents for Alzheimer's disease (AD). Structural modifications of the 4-phenylhydrazono group led to the identification of several highly potent COX-2 inhibitors, with compound 3 exhibiting the strongest COX-2 inhibition (IC50 = 0.07 μM), with a balanced COX-2/COX-1 profile, suggesting lower cardiovascular risk. Compounds 2 and 9 showed high potency and selectivity shift toward COX-1 and displayed strong antiplatelet activity. Several derivatives showed 4–7 times improved submicromolar cellular potency, significantly inhibiting PGE2 release in LPS-stimulated THP-1 cells. Compounds 2, 3, 7, and 9 maintained the multitarget profile and inhibited Aβ and tau aggregation. Compounds 2, 3, and 7 protected against Amyloid-beta (Aβ)- and H2O2-induced cytotoxicity, confirming their neuroprotective activity with high potential for BBB permeability demonstrated via PAMPA and MDCK-MDR1 assays. These results support the potential of multitargeted COX-2 inhibitors as AD therapeutics and suggest a re-evaluation of their role in neurodegenerative disease treatment.

原文英語
文章編號118261
期刊European Journal of Medicinal Chemistry
卷302
DOIs
出版品狀態已出版 - 15 01 2026

文獻附註

Publisher Copyright:
© 2025 Elsevier Masson SAS

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

指紋

深入研究「Revisiting COX-2 inhibitors for Alzheimer's disease as multitargeted ligands: Development of 4-hydrazono-pyrazolidinediones with tuned COX selectivity profile and improved cellular potency」主題。共同形成了獨特的指紋。

引用此